Table 1.
In vitro inhibitory activities of the tasiamide analogues (IC50 (µM) a).
| Compounds | KB b | A549 b | Compounds | KB b | A549 b |
|---|---|---|---|---|---|
| Etoposide c | 0.85 ± 0.08 | 0.99 ± 0.09 | C5 | 2.45 ± 0.41 | 5.24 ± 1.12 |
| T2 | 0.58 ± 0.07 | >50 | C6 | 8.52 ± 1.41 | 12.88 ± 1.32 |
| S1 | >50 | >50 | C7 | 3.80 ± 0.46 | 3.67 ± 0.66 |
| S2 | >50 | >50 | C8 | 3.64 ± 0.55 | >50 |
| S3 | >50 | >50 | C9 | >50 | >50 |
| S4 | >50 | >50 | N1 | >50 | >50 |
| C1 | 3.21 ± 0.6 | 4.17 ± 0.51 | N2 | >50 | >50 |
| C2 | 8.26 ± 1.22 | >50 | M1 | >50 | >50 |
| C3 | 2.08 ± 0.33 | 2.24 ± 0.44 | M2 | >50 | >50 |
| C4 | 1.29 ± 0.31 | 8.48 ± 1.39 | M3 | >50 | >50 |
a The concentration of compound that inhibits 50% (IC50, µM) of the growth of human tumor cell line after 72 h of drug exposure. IC50 values are taken as the means ± standard deviation from three independent experiments; b KB, human nasopharyngeal carcinoma cell line; A549, human non-small cell lung tumor cell line; c Used as a positive control.